Clinical Trial: Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07710885) titled 'Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer' on July 03.

Brief Summary: To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer

Study Start Date: June 24

Study Type: INTERVENTIONAL

Condition: Biliary Tract Cancer

Intervention: DRUG: Futibatinib

Futibatinib 20 mg will be administered orally once daily.

DRUG: Zimberelimab

Zimberelimab 360 mg will be administered on Day 1 of each 3-week cycle (Q3W...